The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | TACTIC-2: TAC01-HER2, a TAC T-cell therapy, in HER2+ tumors
Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, discusses findings from the Phase I TACTIC-2 trial (NCT04727151) of TAC01-HER2, a novel HER2-directed TAC T-cell therapy, in solid tumors. The investigational cellular therapy was found to be safe in patients, and efficacious in gastroesophageal junction (GEJ) cancer but not in breast cancer. Potential reasons include the small, pretreated cohort, and the tumor microenvironment. A Phase II trial with the addition of checkpoint inhibitors is planned in patients with GEJ cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
